CNBC caught up with Biogen CEO George Scangos to discuss where he leaves the big biotech after six years at the helm. » Read More
Horizon Pharma has hired Bank of America to help it explore selling a significant equity stake to an investor that would bolster its balance sheet.
The drug, a treatment option for people with Lennox-Gastaut syndrome, has been shown to reduce the number of monthly seizures in some patients.
Teva Pharmaceutical Industries' Yitzhak Peterburg says business is running as usual as it is still too early to determine Brexit's impact.
The shock result of the U.K.'s referendum on its future in the European Union has led to fears about how Brexit will impact job recruitment.
Inovio's Zika vaccine will be the 14th drug the company has in testing, but its CEO insisted Tuesday the company is not spread too thin.
Opko Health rose more than 5 percent after the U.S. Food and Drug Administration approved the drug Rayaldee.
High-priced drugs have driven health care spending for years, but PwC’s Health research institute sees a shift happening next year. Bertha Coombs sits down with PwC partner Barbara Gniewek to the outlook for 2017 health care spending trends.
Sam Waksal, Kadmon founder, shares his thoughts on the Theranos scandal and its impact on the pharmaceutical industry.
Sam Waksal, Kadmon founder, talks about the division in the pharmaceutical industry.
Twitter, Celgene and Best Buy are making headlines this Wednesday morning.
Some common weight-loss drugs seem to work better than others, according to a new study in a respected medical journal.
A new device that drains a portion of a person's stomach contents after every meal, has just won approval from the U.S. Food and Drug Administration.
Valeant Joseph Papa CEO met with shareholders outlining his stabilization plan to rebuild the company's reputation amid accusations.
Shares of Agios Pharmaceuticals briefly popped more than 8 percent after reporting encouraging data on its lead drug.
Valeant rose about 3 percent in the premarket on the heels of CEO Joseph Papa buying a large amount of the company's stock.
CNBC's Sharon Epperson asks portfolio managers David Pearl, John Maloney and Nick Galluccio their picks on the best deals in the short term.
Walgreens says it will close all 40 Theranos Wellness Centers and will no longer offer any Theranos services at any of its stores.
Former employees of Insys Therapeutics were arrested for allegedly participating in kickback schemes involving doctors who prescribed the company's main drug, Subsys.
Shares of Walgreens and Rite Aid skyrocketed around 4 percent amid reports that the FTC is likely to approve Walgreens' acquisition of Rite Aid.
Mylan shares shed more than 5 percent after Wells Fargo Securities analysts said they were worried about the firm's pricing practices.
Get the best of CNBC in your inbox